In prespecified exploratory analyses, progression-free survival also favored relatlimab–nivolumab over nivolumab across key subgroups (Figure 2). In both treatment groups, the median progression-free survival estimates were longer for patients with LAG-3 expression of 1% or greater...Among patients with PD-L1 expression of less than 1%, the median progression-free survival with relatlimab–nivolumab was 6.4 months (95% CI, 4.6 to 11.8) as compared with 2.9 months (95% CI, 2.8 to 4.5) with nivolumab (hazard ratio, 0.66 [95% CI, 0.51 to 0.84]).